Triethylamine → 1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-3-[2-methyl-4-(6-methyl-3,4-dihydro-2H-quinoline-1-carbonyl)-phenyl]-propan-1-one
反応式
[CH3:1][C:2]([CH3:26])([CH3:25])[CH2:3][CH2:4][N:5]1[CH2:10][CH2:9][N:8]([C:11](=[O:24])[CH2:12][CH2:13][C:14]2[CH:22]=[CH:21][C:17]([C:18](O)=[O:19])=[CH:16][C:15]=2[CH3:23])[CH2:7][CH2:6]1.C(N(CC)CC)C.[CH3:34][C:35]1[CH:36]=[C:37]2[C:42](=[CH:43][CH:44]=1)[NH:41][CH2:40][CH2:39][CH2:38]2>CN(C1C=CN=CC=1)C.ClCCl>[CH3:1][C:2]([CH3:26])([CH3:25])[CH2:3][CH2:4][N:5]1[CH2:6][CH2:7][N:8]([C:11](=[O:24])[CH2:12][CH2:13][C:14]2[CH:22]=[CH:21][C:17]([C:18]([N:41]3[C:42]4[C:37](=[CH:36][C:35]([CH3:34])=[CH:44][CH:43]=4)[CH2:38][CH2:39][CH2:40]3)=[O:19])=[CH:16][C:15]=2[CH3:23])[CH2:9][CH2:10]1参加物
反応物 3
生成物 1
試薬・触媒・溶媒 2
実験手順
DMAP (51 mg, 0.42 mmol) and WSCD (161 mg, 0.84 mmol) were added to a solution of 4-{3-[4-(3,3-dimethyl-butyl)-piperazin-1-yl]-3-oxo-propyl}-3-methyl-benzoic acid from Example E44 (150 mg, 0.42 mmol) in dichloromethane (10 ml) and triethylamine (0.176 ml, 1.26 mmol) and the mixture was stirred for 30 min at room temperature. 6-Methyl-1,2,3,4-tetrahydro-quinoline (67 mg, 0.46 mmol) was added and the mixture was stirred for 20 h at room temperature then solvents were removed in vacuo. The residue was redissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane) to give a white solid identified as the title compound (12 mg, 6%).
後処理
- customsolvents were removed in vacuo
- dissolutionThe residue was redissolved in EtOAC
- washwashed with saturated NaHCO3
- dry with materialbrine, dried
- concentrationconcentrated in vacuo
- customThe residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia:9.5% methanol:90% dichloromethane)
- customto give a white solid
出典と根拠
- ORDレコード
- ord-507054cd9dd44cf99cac82d3144d3ac4
- 出典データセット
- uspto-grants-2012_06
- 特許番号
- US08202858B2
反応ノート
読み込み中…